Aditx Therapeutics Inc
NASDAQ:ADTX
| Market Cap (Intraday) | 39.01M |
| Current PE | N/A |
| Forward PE | 12.59 |
| 2yr Forward PE | 3.08 |
| 10-Day MA | $2.81 |
| 50-Day MA | $2.69 |
| 200-Day MA | $2.56 |
Aditx Therapeutics Inc Stock, NASDAQ:ADTX
2569 Wyandotte Street, Suite 101, Mountain View, California 94043
United States of America
Phone: +1.909.488.0844
Number of Employees: 43
Description
ADiTx Therapeutics, Inc. engages in the development of biotechnologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring. It has a worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.